Gilead Sciences (GILD) Construction in Progress (2010 - 2025)

Gilead Sciences (GILD) reported Construction in Progress of $745.0 million for Q4 2025, up 48.7% on a YoY basis from $501.0 million in Q4 2024, and up 48.7% quarter-over-quarter from $501.0 million in Q4 2024.

Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends

Gilead Sciences has reported Construction in Progress for 16 years, with the latest figure at $745.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Construction in Progress rose 48.7% year-over-year to $745.0 million; the trailing twelve-month figure through Dec 2025 stood at $745.0 million (up 48.7% YoY), and the FY2025 full-year result was $745.0 million, up 48.7% from the prior year.
  • Construction in Progress for Q4 2025 stood at $745.0 million, up from $501.0 million in the prior quarter.
  • The five-year high for Construction in Progress was $1.1 billion in Q4 2021, with the low at $501.0 million in Q4 2024.
  • Historically, Construction in Progress has averaged $736.6 million across 5 years, with a median of $719.0 million in 2022.
  • Annual changes were most pronounced in 2022 — Construction in Progress tumbled 31.98% — and 2025, when it jumped 48.7%.
  • Gilead Sciences' Construction in Progress stood at $1.1 billion in 2021, then plunged by 31.98% to $719.0 million in 2022, then retreated by 8.07% to $661.0 million in 2023, then retreated by 24.21% to $501.0 million in 2024, then jumped by 48.7% to $745.0 million in 2025.
  • The last three Construction in Progress figures came in at $745.0 million (Q4 2025), $501.0 million (Q4 2024), and $661.0 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn -
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn -
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn -
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn -
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn -
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn -
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn -
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 1.54 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 745.00 Mn
Dec 31, 2024 501.00 Mn
Dec 31, 2023 661.00 Mn
Dec 31, 2022 719.00 Mn
Dec 31, 2021 1.06 Bn
Dec 31, 2020 856.00 Mn
Dec 31, 2019 723.00 Mn
Dec 31, 2018 1.19 Bn
Dec 31, 2017 690.00 Mn
Dec 31, 2016 641.00 Mn
Dec 31, 2015 554.00 Mn
Dec 31, 2014 411.00 Mn
Dec 31, 2013 129.00 Mn
Dec 31, 2012 216.43 Mn
Dec 31, 2011 60.75 Mn
Dec 31, 2010 82.33 Mn